1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible...

1. Low dose Olanzapine (2.5 mg) demonstrated similar anti-emetic effect to standard dose olanzapine in patients receiving emetogenic chemotherapy 2....

1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy does not improve overall survival in comparison...

1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year survival. 2. In the...

1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem cell transplantation, rituximab maintenance therapy prolonged...

1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant,...